恆和集團(00513.HK)中期純利1780.5萬港元 同比增長162.30%
格隆匯 2 月 25日丨恆和集團(00513.HK)公佈,截至2020年12月31日止6個月,實現收益2.89億港元,同比增長1.06%;公司擁有人應占溢利1780.5萬港元,同比增長162.30%;每股基本盈利0.26港仙,不派息。
雖然現時珠寶業的前景仍然未明,惟集團已加強競爭力,有信心會走出期內的困境。全球實施嚴緊的防疫措施,加上疫苗面世,預期會為遏止COVID-19大流行擴散起到作用。
集團深信客户信心將會逐步重建,而經濟勢頭將於下半年復甦。本集團為更有力把握網上渠道的增長需求,將會繼續積極提升旗下網上業務及平台,以及加強地方據點及給予客户的支援。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.